目的 探讨黄芪注射液联合重组人干扰素α2a栓治疗宫颈癌前病变的临床疗效。方法 选取2012年3月-2015年6月邢台市人民医院妇产新生儿院区收治的宫颈癌前病变患者90例，按就诊顺序分为对照组与治疗组，每组各45例。对照组患者月经干净后3～4 d，睡前重组人干扰素α2a栓放入阴道后穹窿，1枚/次，隔日1次，经期停药，用药45次。治疗组在对照组的基础上静脉滴注黄芪注射液，10～20 mL/次，1次/d，经期停药，治疗45 d。评价两组临床疗效，比较两组CD3⁺、CD4⁺、CD8⁺及NK细胞活性的变化，观察治疗前后患者阴道清洁度的变化。结果 治疗后，对照组和治疗组总有效率分别为71.11%和88.89%，两组总有效率比较差异具有统计学意义（P<0.05）。治疗后，两组CD3⁺、CD4⁺、CD8⁺和NK水平均显著升高（P<0.05）；且治疗组这些观察指标的升高程度优于对照组（P<0.05）。治疗后，两组Ⅰ～Ⅱ级阴道清洁度例数明显升高，Ⅲ～Ⅳ级例数明显降低，同组治疗前后差异具有统计学意义（P<0.05）；且治疗组上述阴道清洁度例数变化比对照组更明显（P<0.05）。结论 黄芪注射液联合重组人干扰素α2a栓治疗宫颈癌前病变能够显著改善患者机体免疫功能和提升阴道清洁度，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Huangqi Injection combined with Recombinant Human Interferon α2a Vaginal Suppository in treatment of cervical precancerous lesions. Methods Patients (90 cases) with cervical precancerous lesions in Maternity and Newborn Hospital Section of Xingtai People's Hospital from March 2012 to June 2015 were divided into the control and treatment groups according to the visiting sequence, and each group had 45 cases. After menstruation was clean for 3-4 d, the patients in the control group were given Recombinant Human Interferon α2a Vaginal Suppository at posterior vaginal fornix before bedtime every other day for 45 times medication, 1 suppository/time, menstrual withdrawal. The patients in the treatment group were iv administered with Huangqi Injection on the basis of the control group, and treated for 45 d, 10-20 mL/time, once daily, menstrual withdrawal. After treatment, the clinical efficacy was evaluated, CD3⁺, CD4⁺, CD8⁺, and NK in two groups were compared, and the change of vaginal cleanliness was observed. Results After treatment, the clinical efficacy in the control and treatment group were 71.11% and 88.89%, respectively, and there were differences between two groups (P<0.05). After treatment, CD3⁺, CD4⁺, CD8⁺, and NK levels in two groups were significantly increased (P<0.05), And compared with the control group, these observation indexes in treatment group were better than those in the control group (P<0.05). After treatment, the cases of Ⅰ-Ⅱ degree vaginal cleanliness in two groups was significantly increased, the cases of Ⅲ-Ⅳ degree was decreased, and the difference was statistically significant in the same group (P<0.05). And the change of vaginal cleanliness cases in the treatment group was more significant than that in the control group, with significant difference between two groups (P<0.05). Conclusion Huangqi Injection combined with Recombinant Human Interferon α2a Vaginal Suppositories can significantly improve the immune function and enhance vaginal cleanliness in treatment of cervical precancerous lesions, which has a certain clinical application value.